Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors: Are There Clinically Relevant Differences?
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Slower tapering will provide more time for these neuroadaptations and are likely to diminish withdrawal severity 33,44,47 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [47]
In the citing paper
“Notably, decreasing medication by constant amounts (linear tapering) tends to cause increasingly severe side effects 47,50,51 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [47]
In the citing paper
“Withdrawal regimes for benzodiazepines recommend dosage reductions that are proportional to the current dose (most commonly suggesting 10% reductions), yielding exponentially decreasing regimes, as opposed to linear reductions 47,51,53 (Figure 2b).”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [47]
In the citing paper
“However, withdrawal effect from other medications do not observe threshold effects 47,50 , and withdrawal effects have been observed at many doses during tapering of SSRIs 9,36 , suggesting withdrawal is likely to be continuous entity.”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [47]
In the citing paper
“The authors did not report information on the duration of the withdrawal syndromes, probably because symptoms were treated reintroducing fluoxetine [10,57,58] or administering other drugs [1,5] .”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [10]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303 · cited 3×
“The most frequently reported symptom across studies of discontinuation of SSRIs is that of dizziness,[7–10] which is described as ‘swimming’, ‘spaced out’ and ‘drunken’ sensations that are frequently exacerbated by head and eye movements and may be severe.”
BackgroundParoxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
[Treatment of depressive states with an iminodibenzyl derivative (G 22355)].
KUHN, R. (1957) · PubMed · Cited by 242
PRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171
The SSRI discontinuation syndrome
Haddad, P. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200311 · Cited by 126
Newer antidepressants and the discontinuation syndrome.
Haddad, P. M. (1997) · PubMed · Cited by 101
Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system
Stahl, M. M. S., Lindquist, M., Pettersson, M., Edwards, I. R., Sanderson, J. H., Taylor, N. F. A., Fletcher, A. P., & Schou, J. S. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050357 · Cited by 97
Safety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study
Zajecka, J., Fawcett, J., Amsterdam, J., Quitkin, F., Reimherr, F., Rosenbaum, J., Michelson, D., & Beasley, C. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199806000-00003 · Cited by 85
Cited by
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
Metadata
- Authors
- Olver, J. S., Burrows, G. D., & Norman, T. R.
- Affiliations
- The University of Melbourne (AU)
- Corresponding author
- Olver, James S.
- ORCID
- Norman, Trevor R.
- Venue
- CNS Drugs
- Published
- 1999
- Volume
- 12
- Issue
- 3
- Pages
- 171-177
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W1983590524
- Semantic Scholar
- fd7f466a9477f990bf37214e15c454b5edcb7415
- Cited by
- 22
- References
- 13
- Citations by year
- 2024: 1 · 2022: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2013: 1
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- selective serotonin reuptake inhibitors, paroxetine, fluoxetine, adverse drug reactions, antidepressant discontinuation, pharmacokinetics, pharmacodynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors: Are There Clinically Relevant Differences? https://app.cochat.ai/papers/10.2165/00023210-199912030-00001
- The paper
- Olver, J. S., Burrows, G. D., & Norman, T. R. (1999). Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors: Are There Clinically Relevant Differences? CNS Drugs. https://doi.org/10.2165/00023210-199912030-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.